InMed Pharmaceuticals Inc. reported a net loss of approximately $8.2 million for the fiscal year ending June 30, 2025, compared to a loss of $7.7 million in the previous year. The company's total revenue for the year was approximately $4.9 million, reflecting an 8% increase from $4.6 million in 2024. This growth in revenue was primarily attributed to expanded marketing efforts and increased demand for certain cannabinoid products from its subsidiary, BayMedica, which specializes in the commercialization of bulk rare cannabinoids for the health and wellness sector.
The company's operating expenses rose slightly to $9.7 million from $9.3 million in the prior year, driven by increased general and administrative costs, which rose by 7% to $6.6 million. Research and development expenses decreased by 8% to $2.9 million, largely due to reduced external contractor costs. InMed's accumulated deficit reached approximately $117.2 million as of June 30, 2025, indicating ongoing financial challenges as the company continues to invest heavily in its drug development pipeline.
InMed's product pipeline includes three key drug candidates: INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755 for epidermolysis bullosa. The company has made significant progress in its research and development efforts, including the completion of a Phase 2 clinical trial for INM-755, which showed promising results in enhancing anti-itch activity. The company is actively seeking strategic partnerships to further develop INM-755 and other candidates, as it does not currently have a commercial sales organization.
As of June 30, 2025, InMed had approximately $11.1 million in cash and cash equivalents, which is expected to fund operations into the fourth quarter of calendar 2026. However, the company has raised concerns about its ability to continue as a going concern, given its history of operating losses and the need for additional capital to support ongoing research and development activities. InMed plans to seek further funding through equity and debt financing, but there is no assurance that it will be able to secure the necessary capital on favorable terms.
Looking ahead, InMed anticipates increased research and development expenses as it advances its drug candidates through clinical trials and seeks regulatory approvals. The company is also focused on optimizing its manufacturing processes through its proprietary IntegraSyn technology, which aims to produce cannabinoids more efficiently. Despite the challenges, InMed remains committed to its long-term strategy of developing innovative therapies for diseases with high unmet medical needs.
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals develops proprietary small molecule drug candidates targeting the endocannabinoid system to treat high unmet medical needs such as Alzheimer’s disease, dry AMD, and epidermolysis bullosa. The company combines innovative research with diverse manufacturing approaches, including biosynthesis and proprietary platforms, to develop and commercialize pharmaceutical and wellness products. Its core focus is on neuroprotection, anti-inflammatory therapies, and rare cannabinoids for medical and health sectors.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.